HIV

Canaccord Genuity said in note Tuesday the Gates Foundation agreement helps open up the spigot for OraSure Technologies, Inc. (NASDAQ: OSUR). The firm lifted its price target in the wake of the news. Canaccord noted that the deal is similar to Danaher Corporation (NYSE: DHR) unit Cepheid's TB...

On Wednesday, Inovio Pharmaceuticals Inc (NASDAQ: INO) announced the results of a study on its HIV vaccine, PENNVAX-GP, stating the drug “produced amongst the highest overall levels of immune response rates ever demonstrated in a human study by an HIV vaccine.” Benzinga was unable to...

Following the results release of an early-stage study of Pennvax-GP, Inovio Pharmaceuticals Inc (NASDAQ: INO)'s HIV vaccine, H.C. Wainwright noted that the vaccine elicited high T-cell and antibody immune responses in healthy and uninfected adults. The Trial Analysts Raghuram Selvaraju and Yi Chen...

BMO Capital Markets' M. Ian Somaiya maintained a Market Perform rating on Gilead Sciences, Inc. (NASDAQ: GILD) with a price target boosted from $75 to $76 after the company reported its first quarter results. Gilead's reported revenues of $6.5 billion fell short of the $6.66 billion...

Engineering graduate Ram Mukunda spent more than 25 years working in Wall Street. He served in companies communications firms Intelsat SA (NYSE: I) and Startec, before making an incursion into the mining industry through a company he co-founded. India Globalization Capital, Inc. (NYSE: IGC) was...

The Washington Post, citing a Centers for Disease Control and Prevention study, reported the number of annual HIV diagnoses has dropped by 19 percent between 2005 and 2014. Men who have sex with other men accounted for around 67 percent of all HIV diagnoses in 2014. HIV cases among women fell by...

Wendy Lam of Oppenheimer maintained an Outperform rating on shares of Gilead Sciences, Inc. (NASDAQ: GILD) and Perform rating on shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Lam noted that Gilead's two core franchises offer a "durable foundation" of substantial...

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading higher by more than 4 percent Wednesday after the company reported better-than-expected earnings for its second quarter. Here are opposing views of what two of Wall Street's top analysts are saying. Bank Of America: Long-Term...

In 2009, a Canadian baker named Owen Smith was charged with trafficking and unlawful possession of marijuana for using cannabis oil to bake pot cookies. Smith was later acquitted, but a larger question loomed as to whether or not dispensaries in Canada should allow medical marijuana to be...

According to a recent article in Nature, an experimental drug being tested at the Scripps Research Institute in Florida has been effective in blocking HIV infection in monkeys. The new drug has yet to be tested on humans, but preliminary results in animal testing have researchers excited about...

The current Ebola crisis has stolen headlines from other major diseases. One of them is HIV. On November 4, a group of French scientists brought HIV back to the forefront when they announced they had found the genetic mechanism for a “spontaneous cure” of the dreaded disease....

This month marks 33 years since the U.S. Centers for Disease Control and Prevention (CDC) reported on a rare lung infection affecting a group of gay men – one of the first known medical mentions of what later became known as the AIDS outbreak. The World Health Organization says that, over...

In a bull market, investors pile into large cap stocks to ride the wave. With the Standard & Poor's 500 Index up more than 22 percent for the last year of market action, that has certainly been the case. For the savvy investors, that offers promising opportunities in many small caps that...